1. Murthy RS. National Mental Health Survey of India 2015-2016. Indian J Psychiatry 2017; 59(1): 21-6.
2. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256(11): 1449-55.
3. van IeperenL. Sudden death during disulfiram-ethanol reaction. S Afr Med J 1984; 66(5): 165.
4. Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Saf 1999; 20(5): 427-35.
5. Sinclair JM, Chambers SE, Shiles CJ, Baldwin DS. Safety and tolerability of pharmacological treatment of alcohol dependence: Comprehensive review of evidence. Drug Saf 2016; 39(7): 627-45.
6. Goh ET, Morgan MY. Review article: Pharmacotherapy for alcohol dependence - the why,
the what and the wherefore. Aliment Pharmacol Ther 2017; 45(7): 865-82.
7. Plosker GL. Acamprosate: A review of its use in alcohol dependence. Drugs 2015; 75(11): 1255-68.
8. Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, et al. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 2014; 39(4): 783-91.
9. Oscar MA, Bataillon C, Bagheri H, Le Quellec A, Rolland F, Montastruc JL. Acamprosate (Aotal): could adverse effects upset the treatment of alcohol dependence? Therapie 2003; 58(4): 371-4. [In French].
10. Sidana AK, Mangla D. Unusual side effects with acamprosate. Indian J Psychiatry 2007; 49(2): 143.
11. Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol 2014; 77(2): 315-23.